Waldenström’s Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy

References

• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):110–115. doi:10.1053/sonc.2003.50082
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi:10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• Hunter Z, Xu L, Zhou Y, et al. Whole-genome sequencing results from 30 patients with waldenstrom’s macroglobulinemia. Blood. 2011;118(21):434. doi:10.1182/blood.V118.21.434.434
   Web of Science ®Google Scholar
• Lynch RC, Gratzinger D, Advani RH. Clinical impact of the 2016 update to the WHO lymphoma classification. Curr Treat Options Oncol. 2017;18(7):45. doi:10.1007/s11864-017-0483-z
   Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833. doi:10.1056/NEJMoa1200710
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791–2796. doi:10.1182/blood-2014-01-550905
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637–1646. doi:10.1182/blood-2013-09-525808
   PubMed Web of Science ®Google Scholar
• Pophali PA, Bartley A, Kapoor P, et al. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014–1017. doi:10.1111/bjh.15201
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–582. doi:10.1046/j.1365-2141.2001.03144.x
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Koshiol J, Goldin LR, et al. Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):23–26. doi:10.3816/CLM.2009.n.004
   Google Scholar
• Treon SP, Tripsas C, Hanzis C, et al. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2012;12(6):433–437. doi:10.1016/j.clml.2012.08.006
   PubMed Web of Science ®Google Scholar
• Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297(18):2010–2017. doi:10.1001/jama.297.18.2010
   PubMed Web of Science ®Google Scholar
• Mailankody S, Landgren O. Monoclonal gammopathy of undetermined significance and Waldenström’s macroglobulinemia. Best Pract Res Clin Haematol. 2016;29(2):187–193. doi:10.1016/j.beha.2016.08.015
   Web of Science ®Google Scholar
• Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249. doi:10.1056/NEJMoa1709974
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468(3):259–275. doi:10.1007/s00428-015-1858-9
   Web of Science ®Google Scholar
• Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–87.
   PubMedGoogle Scholar
• Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022–2035. doi:10.1182/blood.2019000725
   PubMed Web of Science ®Google Scholar
• Ciccarelli BT, Patterson CJ, Hunter ZR, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):160–163. doi:10.3816/CLML.2011.n.038
   PubMed Web of Science ®Google Scholar
• Samba-Mondonga M, Calvé A, Mallette FA, Santos MM. MyD88 regulates the expression of SMAD4 and the iron regulatory hormone hepcidin. Front Cell Dev Biol. 2018;6:105. doi:10.3389/fcell.2018.00105
   Web of Science ®Google Scholar
• Castillo JJ, Garcia‐Sanz R, Hatjiharissi E. Recommendations for the diagnosis and initial evaluation of patients with waldenström macroglobulinaemia: a task force from the 8th international workshop on waldenström macroglobulinaemia. Br J Haematol. 2016;175:77.
   Web of Science ®Google Scholar
• Banwait R, Aljawai Y, Cappuccio J, et al. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015;90(2):100–104. doi:10.1002/ajh.23880
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019;187(3):277–285. doi:10.1111/bjh.16167
   PubMed Web of Science ®Google Scholar
• Muñiz C, Martín-Martín L, López A, et al. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood. 2014;123(12):1864–1869. doi:10.1182/blood-2013-11-537993
   PubMed Web of Science ®Google Scholar
• Gertz MA. Acute hyperviscosity: syndromes and management. Blood. 2018;132(13):1379–1385. doi:10.1182/blood-2018-06-846816
   PubMed Web of Science ®Google Scholar
• Gustine JN, Meid K, Dubeau T, et al. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017;177(5):717–725. doi:10.1111/bjh.14743
   PubMed Web of Science ®Google Scholar
• Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129(3):289–298. doi:10.1182/blood-2016-09-719773
   PubMed Web of Science ®Google Scholar
• Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166(19):2101–2108. doi:10.1001/archinte.166.19.2101
   PubMedGoogle Scholar
• Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol. 2020;11:590. doi:10.3389/fimmu.2020.00590
   PubMed Web of Science ®Google Scholar
• D’Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017;176(5):728–742. doi:10.1111/bjh.14492
   PubMed Web of Science ®Google Scholar
• Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017;92(5):838–850. doi:10.1016/j.mayocp.2017.02.003
   PubMed Web of Science ®Google Scholar
• Le Cann M, Bouhour F, Viala K, et al. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. Blood. 2020;136(21):2428–2436. doi:10.1182/blood.2020007092
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Garcia-Sanz R, Hatjiharissi E, et al. Recommendations for the diagnosis and initial evaluation of patients with waldenström macroglobulinaemia: a task force from the 8th international workshop on waldenström macroglobulinaemia. Br J Haematol. 2016;175(1):77–86. doi:10.1111/bjh.14196
   PubMed Web of Science ®Google Scholar
• Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020;34(5):1373–1382. doi:10.1038/s41375-019-0667-6
   PubMed Web of Science ®Google Scholar
• Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. Best Pract Res Clin Haematol. 2016;29(2):241–248. doi:10.1016/j.beha.2016.08.013
   Web of Science ®Google Scholar
• Sachchithanantham S, Roussel M, Palladini G, et al. European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin m-related light chain amyloidosis. J Clin Oncol. 2016;34(17):2037–2045. doi:10.1200/JCO.2015.63.3123
   PubMed Web of Science ®Google Scholar
• Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):860–862. doi:10.1093/annonc/mdy466
   Web of Science ®Google Scholar
• Andrade-Campos M, Murillo-Flórez I, García-Sanz R, Giraldo P. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. Clin Chem Lab Med. 2017;55(10):1598–1604. doi:10.1515/cclm-2016-0748
   Web of Science ®Google Scholar
• Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1104–1107. doi:10.1080/10428190802074619
   PubMed Web of Science ®Google Scholar
• Itzykson R, Le Garff-tavernier M, Katsahian S, Diemert MC, Musset L, Leblond V. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom’s macroglobulinemia. Haematologica. 2008;93(5):793–794. doi:10.3324/haematol.12107
   Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–2058. doi:10.1182/blood-2012-09-454355
   PubMed Web of Science ®Google Scholar
• Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia. 2018;32(12):2617–2625. doi:10.1038/s41375-018-0197-7
   PubMed Web of Science ®Google Scholar
• Drandi D, Genuardi E, Dogliotti I, et al. Highly sensitive mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. Haematologica. 2018;103(6):1029–1037. doi:10.3324/haematol.2017.186528
   Web of Science ®Google Scholar
• Lin P, Molina TJ, Cook JR, Swerdlow SH. Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. Am J Clin Pathol. 2011;136(2):195–210. doi:10.1309/AJCP8FOIVTB6LBER
   PubMed Web of Science ®Google Scholar
• Paiva B, Montes MC, García-Sanz R, et al. Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia. 2014;28(1):166–173. doi:10.1038/leu.2013.124
   PubMed Web of Science ®Google Scholar
• Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia. 2013;27(8):1722–1728. doi:10.1038/leu.2013.62
   PubMed Web of Science ®Google Scholar
• Hamadeh F, MacNamara SP, Aguilera NS, Swerdlow SH, Cook JR. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Mod Pathol. 2015;28(4):564–574. doi:10.1038/modpathol.2014.120
   Web of Science ®Google Scholar
• Durot E, Kanagaratnam L, Zanwar S, et al. A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2020. doi:10.3324/haematol.2020.262899
   Web of Science ®Google Scholar
• Durot E, Tomowiak C, Michallet AS, et al. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French innovative leukemia organization (FILO). Br J Haematol. 2017;179(3):439–448. doi:10.1111/bjh.14881
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Jiménez C, Puig N, et al. Origin of Waldenstrom’s macroglobulinaemia. Best Pract Res Clin Haematol. 2016;29(2):136–147. doi:10.1016/j.beha.2016.08.024
   PubMed Web of Science ®Google Scholar
• Paiva B, Corchete LA, Vidriales MB, et al. The cellular origin and malignant transformation of Waldenström macroglobulinemia. Blood. 2015;125(15):2370–2380. doi:10.1182/blood-2014-09-602565
   PubMed Web of Science ®Google Scholar
• Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström’s macroglobulinemia. Mod Pathol. 2009;22(6):807–816. doi:10.1038/modpathol.2009.34
   PubMed Web of Science ®Google Scholar
• Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol. 2005;124(3):414–420. doi:10.1309/3G1XDX0DVHBNVKB4
   Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):187–195. doi:10.1053/sonc.2003.50074
   PubMed Web of Science ®Google Scholar
• Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136(1):80–86. doi:10.1111/j.1365-2141.2006.06389.x
   Web of Science ®Google Scholar
• Braggio E, Fonseca R. Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2013;13(2):198–201. doi:10.1016/j.clml.2013.02.015
   Web of Science ®Google Scholar
• Schop RF, Fonseca R. Genetics and cytogenetics of Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):142–145. doi:10.1053/sonc.2003.50075
   Web of Science ®Google Scholar
• García-Sanz R, Dogliotti I, Zaccaria GM, et al. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. Br J Haematol. 2020;192:843.
   Web of Science ®Google Scholar
• Ocio EM, Hernandez JM, Mateo G, et al. Immunophenotypic and cytogenetic comparison of Waldenstrom’s macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma. 2005;5(4):241–245. doi:10.3816/CLM.2005.n.007
   PubMedGoogle Scholar
• Chang H, Samiee S, Li D, et al. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom’s macroglobulinemia: a single center study of 22 cases. Leukemia. 2004;18(6):1160–1162. doi:10.1038/sj.leu.2403369
   Web of Science ®Google Scholar
• Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica. 2013;98(4):649–654. doi:10.3324/haematol.2012.070458
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström’s Macroglobulinemia. N Engl J Med. 2015;373(6):584–586. doi:10.1056/NEJMc1506192
   PubMed Web of Science ®Google Scholar
• Gracia-sanz R. WM, MYD88, and CXCR4: following the thread. J Am Society Hematol. 2016;128:746.
   Google Scholar
• Hunter ZR, Xu L, Tsakmaklis N, et al. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018;2(21):2937–2946. doi:10.1182/bloodadvances.2018022962
   PubMed Web of Science ®Google Scholar
• Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–2528. doi:10.1182/blood-2012-09-457101
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121(22):4504–4511. doi:10.1182/blood-2012-06-436329
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198–1208. doi:10.1200/JCO.19.02314
   PubMed Web of Science ®Google Scholar
• Jiménez C, Chillón M, Balanzategui A, et al. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2014;22(10):768–773. doi:10.1097/PAI.0000000000000020
   Google Scholar
• Schmidt J, Federmann B, Schindler N, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;169(6):795–803. doi:10.1111/bjh.13361
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–2931. doi:10.1158/1078-0432.CCR-09-2329
   PubMed Web of Science ®Google Scholar
• Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges. Leukemia. 2021;35(2):333–345. doi:10.1038/s41375-020-01102-3
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, signaling, and treatment of waldenström macroglobulinemia. J Clin Oncol. 2017;35(9):994–1001. doi:10.1200/JCO.2016.71.0814
   PubMed Web of Science ®Google Scholar
• Varettoni M, Boveri E, Zibellini S, et al. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: a multicentric study of the Rete Ematologica Lombarda (REL) network. Am J Hematol. 2019;94(11):1193–1199. doi:10.1002/ajh.25600
   PubMed Web of Science ®Google Scholar
• Jiménez C, Prieto-Conde MI, García-álvarez M, et al. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. Ann Hematol. 2018;97(3):475–484.
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Venet-Caillault A, et al. Genomic landscape of CXCR4 mutations in waldenström macroglobulinemia. Clin Cancer Res. 2016;22(6):1480–1488. doi:10.1158/1078-0432.CCR-15-0646
   PubMed Web of Science ®Google Scholar
• Jiménez C, Alonso-álvarez S, Alcoceba M, et al. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer J. 2017;7(8):e591. doi:10.1038/bcj.2017.72
   PubMed Web of Science ®Google Scholar
• Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic waldenström macroglobulinemia. J Clin Oncol. 2019;37(16):1403–1411. doi:10.1200/JCO.19.00394
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170. doi:10.1182/blood-2008-08-174961
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for waldenström macroglobulinaemia. Lancet Haematol. 2020;7(11):e827–e837. doi:10.1016/S2352-3026(20)30224-6
   PubMed Web of Science ®Google Scholar